Celebrating 75 years of the European Society of Cardiology, more than 33,000 participants and nearly 6,400 faculty and presenters came together at ESC 2025 in Madrid, Spain (29 August-1 September 2025), to discuss recent advances in clinical and scientific understanding of cardiovascular disease, including updated guidance on dyslipidaemia management, and a wealth of new data from clinical trials of novel agents designed to lower triglyceride levels and reduce the risk of cardiovascular disease and pancreatitis.
Read the reports:
- ESC revises recommendations for TG lowering in new dyslipidaemia focused update
- Registry data support IPE for 1 in 4 patients with ACS
- ESSENCE-TIMI 73b trial results confirm efficacy and safety of olezarsen
- PALISADE and ARCHES-2 open label extensions support sustained efficacy and safety of plozasiran and zodasiran
- ANGPTL3 linked to plaque calcification
- First-in-human data for apoC3 inhibitor, RBD5044
Reporting by Jenny Bryan
